Chinese diabetes medicine approved for use in Pakistan.

BEIJING -- The insulin glargine injections developed by a Chinese pharmaceutical company has been approved for diabetes patients in Pakistan.

The insulin glargine injecta BASAGINE developed received approval for registration (Reg. No. 111178) by the Drug Regulatory Authority of Pakistan (DRAP), China Economic Net (CEN) reported on Friday.

According to the company, it is the first insulin glargine injection (prefilled injection pen) biosimilar drug in Pakistan.

Insulin glargine injection is an essential long-acting insulin analogue product in the treatment of diabetes for its efficacy and safety.

In Pakistan, 33 million people aged 20-79 were living with diabetes in 2021, ranking third in the world after China and India. The prevalence of diabetes among adults aged 20-79 in Pakistan is 30.8 percent, the highest in the world, as per the latest data...